ppanPersonalized Psychiatry and NeurologyPersonalized Psychiatry and Neurology2712-9179V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)10.52667/2712-9179-2025-5-1-16-26ppan-127Research ArticleREVIEWPersonalized approach to prediction and prevention of haloperidol-induced metabolic syndromeGrechkinaV. V.

192019 Saint Petersburg

191167 St. Petersburg

ShnayderN. A.

192019 Saint Petersburg

660022 Krasnoyarsk

Tel.: +7-(812)-620-02-22 (N.A.S.)

naschnaider@yandex.ruV.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; 3 St. Petersburg State Healthcare Institution “City Psychiatric Hospital №6”Russian FederationV.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of RussiaRussian Federation202517032025511626Copyright © Grechkina V.V., Shnayder N.A., 20252025Grechkina V.V., Shnayder N.A.Grechkina V.V., Shnayder N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jppn.ru/jour/article/view/127

Haloperidol (HLP) is a general medication in the treatment of psychotic disorders such as schizophrenia and acute mania. One of HLP’s advantages compared to other antipsychotics, such as olanzapine or clozapine, is its relatively low risk of significant weight gain, making it more suitable for patients requiring strict weight control. However, despite this comparatively favorable profile, some patients may experience moderate weight gain with long-term use of HLP. This side effect can be attributed to several factors. First, HLP affects metabolic processes, which may lead to changes in appetite and reduced physical activity. Second, the drug can increase prolactin levels, which is associated with the development of hyperprolactinemia—a condition that may contribute to weight gain and the emergence of other components of metabolic syndrome, such as insulin resistance. Third, HLP may promote increased oxidative stress, which plays an important role in the pathogenesis of metabolic disorders. These mechanisms underscore the need for monitoring patients on HLP to promptly detect and manage potential metabolic side effects. Objective: To update the knowledge of practicing psychiatrists and clinical pharmacologists about a personalized approach to the prevention of metabolic syndrome in patients with psychiatric disorders when taking HLP. Methods: Full-text articles published from 01.09.2013 to 01.09.2024 were searched in PubMed, Science Direct, eLIBRARY.RU, and Google Scholar. Results: This review analyses and summarizes the results of foreign and domestic studies on the effect of haloperidol on the development of metabolic syndrome, the role of risk factors and hereditary predisposition in the development of HLP -induced metabolic syndrome in patients with psychiatric disorders.

Conclusion: Generalized data on the effect of HLP on the development of metabolic syndrome in patients with psychiatric disorders may be required by psychiatrists and clinical pharmacologists when selecting the dose and duration of haloperidol administration. Predictive pharmacogenetic testing may help to reduce the probability of this adverse drug reaction and increase the compliance of haloperidol therapy.

antipsychotichaloperidolmetabolic syndromeadverse reactionmetabolismobesityhyperglycaemiatype 2 diabetes mellitusinsulin resistancepharmacogenetic testingpsychiatric disorderpreventionThe study was performed within the framework of the state assignment of the”Bekhterev’s National Medical Research Center For Psychiatry and Neurology of the Ministry of Health of Russia” (XSOZ 2024 0012).ReferencesPeltier, M.R.; Mehmet Sofuoglu. Chapter 23 - Pharmacological cognitive enhancers. Cognition and Addiction. 2020, 303-320. doi:10.1016/B978-0-12-815298-0.00023-XPeltier, M.R.; Mehmet Sofuoglu. Chapter 23 - Pharmacological cognitive enhancers. Cognition and Addiction. 2020, 303-320. doi:10.1016/B978-0-12-815298-0.00023-XNasyrova, R.F.; Neznanov, N.G. Clinical psychopharmacogenetics. DEAN. 2020, 408. ISBN 978-5-6043573-7-8Nasyrova, R.F.; Neznanov, N.G. Clinical psychopharmacogenetics. DEAN. 2020, 408. ISBN 978-5-6043573-7-8Nasyrova, R.F.; Kidyaeva, A.V.; Grechkina, V.V.; Shnayder, N.A. Personalized approach to prediction and prevention of haloperidol-induced QT interval prolongation: brief review. Pharmacogenetics and Pharmacogenomics. 2024, (1), 20-30. doi:10.37489/2588-0527-2024-1-20-30Nasyrova, R.F.; Kidyaeva, A.V.; Grechkina, V.V.; Shnayder, N.A. Personalized approach to prediction and prevention of haloperidol-induced QT interval prolongation: brief review. Pharmacogenetics and Pharmacogenomics. 2024, (1), 20-30. doi:10.37489/2588-0527-2024-1-20-30Andersen, M.; Glintborg, D. Metabolic Syndrome in Hyperprolactinemia. Front Horm Res. 2018, 49, 29-47. doi: 10.1159/000486000.Andersen, M.; Glintborg, D. Metabolic Syndrome in Hyperprolactinemia. Front Horm Res. 2018, 49, 29-47. doi: 10.1159/000486000.Mukherjee, S.; Skrede, S.; Milbank, E.; Andriantsitohaina, R.; López, M.; Fernø, J. Understanding the Effects of Antipsychotics on Appetite Control. Front Nutr. 2022, 8, 815456. doi: 10.3389/fnut.2021.815456Mukherjee, S.; Skrede, S.; Milbank, E.; Andriantsitohaina, R.; López, M.; Fernø, J. Understanding the Effects of Antipsychotics on Appetite Control. Front Nutr. 2022, 8, 815456. doi: 10.3389/fnut.2021.815456Vázquez-Carrillo, D.I.; Ocampo-Ruiz, A.L.; Báez-Meza, A.; Ramírez-Hernández, G.; Adán-Castro, E.; García-Rodrigo, J.F.; Dena-Beltrán, J.L.; de Los, Ríos, E.A.; Sánchez-Martínez, M.K.; Ortiz, M.G.; Escalera, M.G.; Clapp, C.; Macotela, Y. Dopamine D2 receptor antagonist counteracts hyperglycemia and insulin resistance in diet-induced obese male mice. PLoS One. 2024, 19(4), e0301496. doi:10.1371/journal.pone.0301496Vázquez-Carrillo, D.I.; Ocampo-Ruiz, A.L.; Báez-Meza, A.; Ramírez-Hernández, G.; Adán-Castro, E.; García-Rodrigo, J.F.; Dena-Beltrán, J.L.; de Los, Ríos, E.A.; Sánchez-Martínez, M.K.; Ortiz, M.G.; Escalera, M.G.; Clapp, C.; Macotela, Y. Dopamine D2 receptor antagonist counteracts hyperglycemia and insulin resistance in diet-induced obese male mice. PLoS One. 2024, 19(4), e0301496. doi:10.1371/journal.pone.0301496Lopez-Vicchi, F.; De, Winne, C.; Brie, B.; Sorianello, E.; Ladyman, S.R.; Becu-Villalobos, D. Metabolic functions of prolactin: Physiological and pathological aspects. J Neuroendocrinol. 2020, 32(11), e12888. doi:10.1111/jne.12888Lopez-Vicchi, F.; De, Winne, C.; Brie, B.; Sorianello, E.; Ladyman, S.R.; Becu-Villalobos, D. Metabolic functions of prolactin: Physiological and pathological aspects. J Neuroendocrinol. 2020, 32(11), e12888. doi:10.1111/jne.12888Ben-Jonathan, N.; LaPensee, C.R.; LaPensee, E.W. What can we learn from rodents about prolactin in humans? Endocr Rev. 2008, 29(1), 1-41. doi:10.1210/er.2007-0017Ben-Jonathan, N.; LaPensee, C.R.; LaPensee, E.W. What can we learn from rodents about prolactin in humans? Endocr Rev. 2008, 29(1), 1-41. doi:10.1210/er.2007-0017Woodside, B. Prolactin and the hyperphagia of lactation. Physiol Behav. 2007, 91(4), 375-82. doi: 10.1016/j.physbeh.2007.04.015Woodside, B. Prolactin and the hyperphagia of lactation. Physiol Behav. 2007, 91(4), 375-82. doi: 10.1016/j.physbeh.2007.04.015Bina, K.G.; Cincotta, A.H. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000, 71(1), 68-78. doi: 10.1159/000054522Bina, K.G.; Cincotta, A.H. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000, 71(1), 68-78. doi: 10.1159/000054522Pirchio, R.; Graziadio, C.; Colao, A.; Pivonello, R.; Auriemma, R.S. Metabolic effects of prolactin. Front Endocrinol. 2022, 13, 1015520. doi:10.3389/fendo.2022.1015520Pirchio, R.; Graziadio, C.; Colao, A.; Pivonello, R.; Auriemma, R.S. Metabolic effects of prolactin. Front Endocrinol. 2022, 13, 1015520. doi:10.3389/fendo.2022.1015520Lopez-Vicchi, F.; Ladyman, S.R.; Ornstein, A.M.; Gustafson, P.; Knowles, P.; Luque, G.M.; Grattan, D.R.; Becu-Villalobos, D. Chronic high prolactin levels impact on gene expression at discrete hypothalamic nuclei involved in food intake. FASEB J. 2020, 34(3), 3902-3914. doi:10.1096/fj.201902357RLopez-Vicchi, F.; Ladyman, S.R.; Ornstein, A.M.; Gustafson, P.; Knowles, P.; Luque, G.M.; Grattan, D.R.; Becu-Villalobos, D. Chronic high prolactin levels impact on gene expression at discrete hypothalamic nuclei involved in food intake. FASEB J. 2020, 34(3), 3902-3914. doi:10.1096/fj.201902357RBalbach, L.; Wallaschofski, H.; Völzke, H.; Nauck, M.; Dörr, M.; Haring, R. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Disord. 2013, 13, 12. doi:10.1186/1472-6823-13-12Balbach, L.; Wallaschofski, H.; Völzke, H.; Nauck, M.; Dörr, M.; Haring, R. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Disord. 2013, 13, 12. doi:10.1186/1472-6823-13-12Ponce, A.J.; Galván-Salas, T.; Lerma-Alvarado, R.M.; Ruiz-Herrera, X.; Hernández-Cortés, T.; Valencia-Jiménez, R.; Cárdenas-Rodríguez, L.E.; Escalera, M.G.; Clapp, C.; Macotela, Y. Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans. Endocrine. 2020, 67(2), 331-343. doi:10.1007/s12020-019-02170-xPonce, A.J.; Galván-Salas, T.; Lerma-Alvarado, R.M.; Ruiz-Herrera, X.; Hernández-Cortés, T.; Valencia-Jiménez, R.; Cárdenas-Rodríguez, L.E.; Escalera, M.G.; Clapp, C.; Macotela, Y. Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans. Endocrine. 2020, 67(2), 331-343. doi:10.1007/s12020-019-02170-xZhang, Y.; Lu, T.; Yan, H.; Ruan, Y.; Wang, L.; Zhang, D.; Yue, W.; Lu, L. Replication of association between schizophrenia and chromosome 6p21-6p22.1 polymorphisms in Chinese Han population. PLoS One. 2013, 8(2), e56732. doi: 10.1371/journal.pone.0056732Zhang, Y.; Lu, T.; Yan, H.; Ruan, Y.; Wang, L.; Zhang, D.; Yue, W.; Lu, L. Replication of association between schizophrenia and chromosome 6p21-6p22.1 polymorphisms in Chinese Han population. PLoS One. 2013, 8(2), e56732. doi: 10.1371/journal.pone.0056732Sinkus, M.L.; Adams, C.E.; Logel, J.; Freedman, R.; Leonard, S. Expression of immune genes on chromosome 6p21.3-22.1 in schizophrenia. Brain Behav Immun. 2013, 32, 51-62. doi:10.1016/j.bbi.2013.01.087Sinkus, M.L.; Adams, C.E.; Logel, J.; Freedman, R.; Leonard, S. Expression of immune genes on chromosome 6p21.3-22.1 in schizophrenia. Brain Behav Immun. 2013, 32, 51-62. doi:10.1016/j.bbi.2013.01.087Ivanova, S.A.; Osmanova, D.Z.; Boiko, A.S.; Pozhidaev, I.V.; Freidin, M.B.; Fedorenko, O.Y.; Semke, A.V.; Bokhan, N.A.; Kornetova, E.G.; Rakhmazova, L.D.; Wilffert, B.; Loonen, A.J. Prolactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophr Res. 2017, 182, 110-114. doi: 10.1016/j.schres.2016.10.029Ivanova, S.A.; Osmanova, D.Z.; Boiko, A.S.; Pozhidaev, I.V.; Freidin, M.B.; Fedorenko, O.Y.; Semke, A.V.; Bokhan, N.A.; Kornetova, E.G.; Rakhmazova, L.D.; Wilffert, B.; Loonen, A.J. Prolactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophr Res. 2017, 182, 110-114. doi: 10.1016/j.schres.2016.10.029Hernández-Bello, J.; Palafox-Sanchez, C.A.; García-Arellano, S.; Reyes-Castillo, Z.; Pereira-Suárez, A.L.; Parra-Rojas, I.; Navarro-Zarza, J.E.; Cruz-Mosso, D.U.; Torres-Carrillo, N.M.; Muñoz-Valle, J.F. Association of extrapituitary prolactin promoter polymorphism with disease susceptibility and anti-RNP antibodies in Mexican patients with systemic lupus erythematosus. Arch Med Sci. 2018,1 4(5), 1025-1032. doi:10.5114/aoms.2016.62138Hernández-Bello, J.; Palafox-Sanchez, C.A.; García-Arellano, S.; Reyes-Castillo, Z.; Pereira-Suárez, A.L.; Parra-Rojas, I.; Navarro-Zarza, J.E.; Cruz-Mosso, D.U.; Torres-Carrillo, N.M.; Muñoz-Valle, J.F. Association of extrapituitary prolactin promoter polymorphism with disease susceptibility and anti-RNP antibodies in Mexican patients with systemic lupus erythematosus. Arch Med Sci. 2018,1 4(5), 1025-1032. doi:10.5114/aoms.2016.62138Lee, Y.C.; Raychaudhuri, S.; Cui, J.; De, Vivo, I.; Ding, B.; Alfredsson, L.; Padyukov, L.; Costenbader, K.H.; Seielstad, M.; Graham, R.R.; Klareskog, L.; Gregersen, P.K.; Plenge, R.M.; Karlson, E.W. The PRL -1149 G/T polymorphism and rheumatoid arthritis susceptibility. Arthritis Rheum. 2009, 60(5), 1250-4. doi:10.1002/art.24468Lee, Y.C.; Raychaudhuri, S.; Cui, J.; De, Vivo, I.; Ding, B.; Alfredsson, L.; Padyukov, L.; Costenbader, K.H.; Seielstad, M.; Graham, R.R.; Klareskog, L.; Gregersen, P.K.; Plenge, R.M.; Karlson, E.W. The PRL -1149 G/T polymorphism and rheumatoid arthritis susceptibility. Arthritis Rheum. 2009, 60(5), 1250-4. doi:10.1002/art.24468Treadwell, E.L.; Wiley, K.; Word, B.; Melchior, W.; Tolleson, W.H.; Gopee, N.; Hammons, G.; Lyn-Cook, B.D. Prolactin and Dehydroepiandrosterone Levels in Women with Systemic Lupus Erythematosus: The Role of the Extrapituitary Prolactin Promoter Polymorphism at -1149G/T. J Immunol Res. 2015, 2015, 435658. doi:10.1155/2015/435658Treadwell, E.L.; Wiley, K.; Word, B.; Melchior, W.; Tolleson, W.H.; Gopee, N.; Hammons, G.; Lyn-Cook, B.D. Prolactin and Dehydroepiandrosterone Levels in Women with Systemic Lupus Erythematosus: The Role of the Extrapituitary Prolactin Promoter Polymorphism at -1149G/T. J Immunol Res. 2015, 2015, 435658. doi:10.1155/2015/435658Duc, Nguyen, H.; Oh, H.; Yu, B.P.; Hoang, N.M.H.; Jo, W.H., Young, Chung, H., Kim, M.S. Associations between Prolactin, Diabetes, and Cognitive Impairment: A Literature Review. Neuroendocrinology. 2022, 112(9), 856-873. doi: 10.1159/000521653Duc, Nguyen, H.; Oh, H.; Yu, B.P.; Hoang, N.M.H.; Jo, W.H., Young, Chung, H., Kim, M.S. Associations between Prolactin, Diabetes, and Cognitive Impairment: A Literature Review. Neuroendocrinology. 2022, 112(9), 856-873. doi: 10.1159/000521653Gierach, M.; Bruska-Sikorska, M.; Rojek, M.; Junik, R. Hyperprolactinemia and insulin resistance. Endokrynol Pol. 2022, 73(6), 959-967. doi:10.5603/EP.a2022.0075Gierach, M.; Bruska-Sikorska, M.; Rojek, M.; Junik, R. Hyperprolactinemia and insulin resistance. Endokrynol Pol. 2022, 73(6), 959-967. doi:10.5603/EP.a2022.0075Yang, H.; Lin, J.; Li, H.; Liu, Z.; Chen, X.; Chen, Q. Prolactin Is Associated With Insulin Resistance and Beta-Cell Dysfunction in Infertile Women With Polycystic Ovary Syndrome. Front Endocrinol. 2021, 12, 571229. doi: 10.3389/fendo.2021.571229Yang, H.; Lin, J.; Li, H.; Liu, Z.; Chen, X.; Chen, Q. Prolactin Is Associated With Insulin Resistance and Beta-Cell Dysfunction in Infertile Women With Polycystic Ovary Syndrome. Front Endocrinol. 2021, 12, 571229. doi: 10.3389/fendo.2021.571229Nilsson, L.; Binart, N.; Bohlooly-Y, M.; Bramnert, M.; Egecioglu, E.; Kindblom, J.; Kelly, P.A.; Kopchick, J.J.; Ormandy, C.J.; Ling, C.; Billig, H. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun. 2005, 331(4), 1120-6. doi:10.1016/j.bbrc.2005.04.026Nilsson, L.; Binart, N.; Bohlooly-Y, M.; Bramnert, M.; Egecioglu, E.; Kindblom, J.; Kelly, P.A.; Kopchick, J.J.; Ormandy, C.J.; Ling, C.; Billig, H. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun. 2005, 331(4), 1120-6. doi:10.1016/j.bbrc.2005.04.026Nguyen, D.H.; Yu, P.B.; Hoang, N.H.M.; Jo, W.H.; Chung, Y.H.; Kim, M.S. Prolactin and Its Altered Action in Alzheimer's Disease and Parkinson's Disease. Neuroendocrinology. 2022, 112(5), 427-445. doi:10.1159/000517798Nguyen, D.H.; Yu, P.B.; Hoang, N.H.M.; Jo, W.H.; Chung, Y.H.; Kim, M.S. Prolactin and Its Altered Action in Alzheimer's Disease and Parkinson's Disease. Neuroendocrinology. 2022, 112(5), 427-445. doi:10.1159/000517798Haile, K.; Haile, A.; Timerga, A. Predictors of Lipid Profile Abnormalities Among Patients with Metabolic Syndrome in Southwest Ethiopia: A Cross-Sectional Study. Vasc Health Risk Manag. 2021, 17, 461- 469. doi:10.2147/VHRM.S319161Haile, K.; Haile, A.; Timerga, A. Predictors of Lipid Profile Abnormalities Among Patients with Metabolic Syndrome in Southwest Ethiopia: A Cross-Sectional Study. Vasc Health Risk Manag. 2021, 17, 461- 469. doi:10.2147/VHRM.S319161Pala, N.A.; Laway, B.A.; Misgar, R.A.; Dar, R.A. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr. 2015, 7, 99. doi:10.1186/s13098-015-0094-4Pala, N.A.; Laway, B.A.; Misgar, R.A.; Dar, R.A. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr. 2015, 7, 99. doi:10.1186/s13098-015-0094-4Bardenstein, L.M.; Mkrtumyan, A.M.; Alyoshkina, G.A. State of carbohydrate and lipid metabolism in patients with paranoid schizophrenia during therapy with atypical antipsychotic drugs. Diabetes Mellitus. 2010, 13(2), 42-44. doi: 10.14341/2072-0351-5672Bardenstein, L.M.; Mkrtumyan, A.M.; Alyoshkina, G.A. State of carbohydrate and lipid metabolism in patients with paranoid schizophrenia during therapy with atypical antipsychotic drugs. Diabetes Mellitus. 2010, 13(2), 42-44. doi: 10.14341/2072-0351-5672Perez-Iglesias, R.; Crespo-Facorro, B.; Martinez-Garcia, O.; Ramirez-Bonilla, M.L.; Alvarez-Jimenez, M.; Pelayo-Teran, J.M.; Garcia-Unzueta, M.T.; Amado, J.A.; Vazquez-Barquero, J.L. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res. 2008, 99(1-3), 13-22. doi:10.1016/j.schres.2007.10.022Perez-Iglesias, R.; Crespo-Facorro, B.; Martinez-Garcia, O.; Ramirez-Bonilla, M.L.; Alvarez-Jimenez, M.; Pelayo-Teran, J.M.; Garcia-Unzueta, M.T.; Amado, J.A.; Vazquez-Barquero, J.L. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res. 2008, 99(1-3), 13-22. doi:10.1016/j.schres.2007.10.022Keulen, K.; Knol, W.; Schrijver, E.J.M.; Marum, R.J.; Strien, A.M.; Nanayakkara, P.W.B. Prophylactic Use of Haloperidol and Changes in Glucose Levels in Hospitalized Older Patients. J Clin Psychopharmacol. 2018, 38(1), 51-54. doi: 10.1097/JCP.0000000000000812Keulen, K.; Knol, W.; Schrijver, E.J.M.; Marum, R.J.; Strien, A.M.; Nanayakkara, P.W.B. Prophylactic Use of Haloperidol and Changes in Glucose Levels in Hospitalized Older Patients. J Clin Psychopharmacol. 2018, 38(1), 51-54. doi: 10.1097/JCP.0000000000000812Vidarsdottir, S.; de Weenen, L.J.E.; Frölich, M.; Roelfsema, F.; Romijn, J.A.; Pijl, H. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab. 2010, 95(1), 118-25. doi:10.1210/jc.2008-1815Vidarsdottir, S.; de Weenen, L.J.E.; Frölich, M.; Roelfsema, F.; Romijn, J.A.; Pijl, H. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab. 2010, 95(1), 118-25. doi:10.1210/jc.2008-1815Parabiaghi, A.; Tettamanti, M.; D'Avanzo, B.; Barbato, A. GiSAS study group. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta Psychiatr Scand. 2016, 133(1), 63-75. doi:10.1111/acps.12468Parabiaghi, A.; Tettamanti, M.; D'Avanzo, B.; Barbato, A. GiSAS study group. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta Psychiatr Scand. 2016, 133(1), 63-75. doi:10.1111/acps.12468Ventriglio, A.; Baldessarini, R.J.; Vitrani, G.; Bonfitto, I.; Cecere, A.C.; Rinaldi, A.; Petito, A.; Bellomo, A. Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics. Front Psychiatry. 2019, 9, 744. doi:10.3389/fpsyt.2018.00744Ventriglio, A.; Baldessarini, R.J.; Vitrani, G.; Bonfitto, I.; Cecere, A.C.; Rinaldi, A.; Petito, A.; Bellomo, A. Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics. Front Psychiatry. 2019, 9, 744. doi:10.3389/fpsyt.2018.00744El-Awdan, S.A.; Gehad A. Abdel, G.A.J., Saleh, D.O. Alleviation of haloperidol induced oxidative stress in rats: Effects of sucrose vs grape seed extract. Bulletin of Faculty of Pharmacy. 2015, 53 (1), 29-35& doi:10.1016/j.bfopcu.2015.02.004El-Awdan, S.A.; Gehad A. Abdel, G.A.J., Saleh, D.O. Alleviation of haloperidol induced oxidative stress in rats: Effects of sucrose vs grape seed extract. Bulletin of Faculty of Pharmacy. 2015, 53 (1), 29-35& doi:10.1016/j.bfopcu.2015.02.004Masenga, S.K.; Kabwe, L.S.; Chakulya, M.; Kirabo, A. Mechanisms of Oxidative Stress in Metabolic Syndrome. Int. J. Mol. Sci. 2023, 24, 7898. doi:10.3390/ijms24097898Masenga, S.K.; Kabwe, L.S.; Chakulya, M.; Kirabo, A. Mechanisms of Oxidative Stress in Metabolic Syndrome. Int. J. Mol. Sci. 2023, 24, 7898. doi:10.3390/ijms24097898Kajero, J.A.; Seedat, S.; Ohaeri, J.U.; Akindele, A.; Aina, O. Effects of cannabidiol on weight and fasting blood sugar with chronic and subchronic haloperidol administration. Discov Ment Health. 2022, 2(1), 18. doi:10.1007/s44192-022-00021-2Kajero, J.A.; Seedat, S.; Ohaeri, J.U.; Akindele, A.; Aina, O. Effects of cannabidiol on weight and fasting blood sugar with chronic and subchronic haloperidol administration. Discov Ment Health. 2022, 2(1), 18. doi:10.1007/s44192-022-00021-2Andreazza, A.C.; Barakauskas, V.E.; Fazeli, S.; Feresten, A.; Shao, L.; Wei, V.; Wu, C.H.; Barr, A.M.; Beasley, C.L. Effects of haloperidol and clozapine administration on oxidative stress in rat brain, liver and serum. Neurosci Lett. 2015, 591, 36-40. doi:10.1016/j.neulet.2015.02.028Andreazza, A.C.; Barakauskas, V.E.; Fazeli, S.; Feresten, A.; Shao, L.; Wei, V.; Wu, C.H.; Barr, A.M.; Beasley, C.L. Effects of haloperidol and clozapine administration on oxidative stress in rat brain, liver and serum. Neurosci Lett. 2015, 591, 36-40. doi:10.1016/j.neulet.2015.02.028Rezaei, F.; Farhat, D.; Gursu, G.; Samnani, S.; Lee, J.Y. Snapshots of ABCG1 and ABCG5/G8: A Sterol's Journey to Cross the Cellular Membranes. Int J Mol Sci. 2022, 24(1), 484. doi:10.3390/ijms24010484Rezaei, F.; Farhat, D.; Gursu, G.; Samnani, S.; Lee, J.Y. Snapshots of ABCG1 and ABCG5/G8: A Sterol's Journey to Cross the Cellular Membranes. Int J Mol Sci. 2022, 24(1), 484. doi:10.3390/ijms24010484Oldfield, S.; Lowry, A.C.; Ruddick, J.; Lightman, L.S. ABCG4: a novel human white family ABC-transporter expressed in the brain and eye. Biochimica et Biophysica Acta (BBA). Molecular Cell Research. 2002, 175-179, doi:10.1016/S0167-4889(02)00269-0Oldfield, S.; Lowry, A.C.; Ruddick, J.; Lightman, L.S. ABCG4: a novel human white family ABC-transporter expressed in the brain and eye. Biochimica et Biophysica Acta (BBA). Molecular Cell Research. 2002, 175-179, doi:10.1016/S0167-4889(02)00269-0Nasyrova, R.F.; Neznanov, N.G. Clinical psychopharmacogenetics. DEAN. 2020, 408.Nasyrova, R.F.; Neznanov, N.G. Clinical psychopharmacogenetics. DEAN. 2020, 408.Kiss, K.; Kucsma, N.; Brozik, A.; Tusnady, G.E.; Bergam, P.; Niel, G.; Szakacs, G. Role of the N-terminal transmembrane domain in the endo-lysosomal targeting and function of the human ABCB6 protein. Biochem J. 2015, 467(1), 127-39. doi: 10.1042/BJ20141085Kiss, K.; Kucsma, N.; Brozik, A.; Tusnady, G.E.; Bergam, P.; Niel, G.; Szakacs, G. Role of the N-terminal transmembrane domain in the endo-lysosomal targeting and function of the human ABCB6 protein. Biochem J. 2015, 467(1), 127-39. doi: 10.1042/BJ20141085Doyle, L.; Ross, D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003, 22(47), 7340-58. doi:10.1038/sj.onc.1206938Doyle, L.; Ross, D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003, 22(47), 7340-58. doi:10.1038/sj.onc.1206938Arduino, I.; Iacobazzi, R.M.; Riganti, C.; Lopedota, A.A.; Perrone, M.G.; Lopalco, A.; Cutrignelli, A.; Cantore, M.; Laquintana, V.; Franco, M.; Colabufo, N.A.; Luurtsema, G.; Contino, M.; Denora, N. Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease. Int J Pharm. 2020, 591, 120011. doi:10.1016/j.ijpharm.2020.120011Arduino, I.; Iacobazzi, R.M.; Riganti, C.; Lopedota, A.A.; Perrone, M.G.; Lopalco, A.; Cutrignelli, A.; Cantore, M.; Laquintana, V.; Franco, M.; Colabufo, N.A.; Luurtsema, G.; Contino, M.; Denora, N. Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease. Int J Pharm. 2020, 591, 120011. doi:10.1016/j.ijpharm.2020.120011OMIM [Accessed September 20, 2024]. Available at: https://www.omim.org/entry/124010?search=Cytochrome%20P450%20isoenzymes%203A4&highlight=3a4%2Ccytochrome%2Cp450OMIM [Accessed September 20, 2024]. Available at: https://www.omim.org/entry/124010?search=Cytochrome%20P450%20isoenzymes%203A4&highlight=3a4%2Ccytochrome%2Cp450OMIM [Accessed September 20, 2024]. Available at: https://www.omim.org/entry/124030?search=CYP2D6&highlight=cyp2d6OMIM [Accessed September 20, 2024]. Available at: https://www.omim.org/entry/124030?search=CYP2D6&highlight=cyp2d6OMIM [Accessed September 20, 2024]. Available at: https://www.omim.org/entry/600068?search=UGT2B7&highlight=ugt2b7OMIM [Accessed September 20, 2024]. Available at: https://www.omim.org/entry/600068?search=UGT2B7&highlight=ugt2b7OMIM [Accessed September 20, 2024]. Available at: https://www.omim.org/entry/604159?search=SLC6A5&highlight=slc6a5OMIM [Accessed September 20, 2024]. Available at: https://www.omim.org/entry/604159?search=SLC6A5&highlight=slc6a5OMIM [Accessed September 20, 2024]. Available at: https://www.omim.org/entry/611785?search=ABCB5&highlight=abcb5OMIM [Accessed September 20, 2024]. Available at: https://www.omim.org/entry/611785?search=ABCB5&highlight=abcb5Shnayder, N.A.; Grechkina, V.V.; Arkhipov, V.V.; Nasyrova, R.F. Role of Pharmacogenetic Testing in the Risk and Safety Assessment of Valproates: The Ethnic Aspect (Review). Safety and Risk of Pharmacotherapy. 2024, 12(2), 132-154. (In Russ.) doi:10.30895/2312-7821-2024-12-2-132-154Shnayder, N.A.; Grechkina, V.V.; Arkhipov, V.V.; Nasyrova, R.F. Role of Pharmacogenetic Testing in the Risk and Safety Assessment of Valproates: The Ethnic Aspect (Review). Safety and Risk of Pharmacotherapy. 2024, 12(2), 132-154. (In Russ.) doi:10.30895/2312-7821-2024-12-2-132-154

The authors declare that there are no conflicts of interest present.